Should You Buy Indivior Pharmaceuticals, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Indivior Pharmaceuticals, Inc. (INDV) carries a solid Quality of Company rating of 7.2/10. Trading at $34.22, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 1 of 9 CirclFi valuation models project upside for Indivior Pharmaceuticals, Inc. (INDV) at $34.22 — the model consensus leans bearish, with a Quality Score of 7.2/10 and Value-Trap risk of 25/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Indivior Pharmaceuticals, Inc. (INDV) in 2026?
What Is the Bull Case vs the Bear Case for Indivior Pharmaceuticals, Inc. (INDV)?
| Bull case — $98.09 target (+186.6%) | Bear case — $2.32 target (-93.2%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Indivior Pharmaceuticals, Inc.'s quality score of 7.2/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $2.32 (-93.2%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $98.09 (+186.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +279.8% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for Indivior Pharmaceuticals, Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: drug pricing legislation represents a meaningful risk for Indivior Pharmaceuticals, Inc. and its Drug Manufacturers - Specialty & Generic peers. |
How Does INDV Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: ELAN · ETON · SUPN · IRWD · TRLV · EBS · INIS · RGC · SXTC · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like INDV on Quality?
Closest companies to INDV’s Quality of Company score of 7.2/10, across all industries.
- YORW — The York Water Company (QOC 7.2) · analysis
- AGNC — AGNC Investment Corp. (QOC 7.2) · analysis
- BTSG — BrightSpring Health Services, Inc. (QOC 7.2) · analysis
- LGCL — Lucas GC Limited (QOC 7.2) · analysis
- ACR — ACRES Commercial Realty Corp. (QOC 7.2) · analysis
- F — Ford Motor Company (QOC 7.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does INDV Appear In?
So Is Indivior Pharmaceuticals, Inc. (INDV) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Indivior Pharmaceuticals, Inc. at $34.22. 8/9 models flag overvaluation, median fair value sits at $18.30 (-46.5%), and the risk-reward profile appears unfavorable. Quality at 7.2/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Indivior Pharmaceuticals, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About INDV Stock?
Should I buy INDV stock right now?
Based on CirclFi's multi-model analysis, 1 of 9 models see upside for INDV at $34.22. The models are divided, which means the investment case depends heavily on your assumptions about Indivior Pharmaceuticals, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Indivior Pharmaceuticals, Inc.?
Key risks include: wide model disagreement (4121% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does INDV compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, INDV holds a Quality Score of 7.2/10. Comparable companies include ELAN (QOC 7.2), ETON (QOC 7.2), SUPN (QOC 7.2). The relative ranking helps investors identify whether INDV offers better fundamental quality than alternatives in the same sector.
Is INDV a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. INDV's Quality Score of 7.2/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy INDV at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $2.32 to $98.09. At $34.22, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for INDV.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad